https://www.onclive.com/onclive-tv/dr-pecora-on-ctla4-and-pd1-combinations-in-multiple-myeloma
Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple Myeloma

Andrew L. Pecora, MD



Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

The rationale behind this combination is that CTLA-4 inhibitors are a true suppressor of T-regulatory cells. Additionally, CTLA-4 works centrally, whereas PD-1 works in the periphery, which makes this an ideal combination, explains Pecora.
 
Printer Printing...